XML 17 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 20,637,045 $ 4,823,544
Short-term investment securities 8,457,452 29,399,146
Interest receivable 112,247 329,711
Accounts receivable 294,199 558,530
Income tax receivable 0 250,308
Prepaid expenses and other current assets 280,555 277,999
Total current assets 29,781,498 35,639,238
Non-current assets:    
Long-term investment securities 0 1,511,636
Long-term income tax receivable 0 250,308
Investment in Alphazyme 284,709 0
Other assets 6,225 51,314
Total assets 30,072,432 37,452,496
Current liabilities:    
Accounts payable 1,013,099 943,378
Accrued expenses 489,756 566,003
Deferred research and development obligations 123,016 78,644
Total current liabilities 1,625,871 1,588,025
Commitments and contingencies (Note 5)
Stockholders’ equity:    
Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding 0 0
Common stock, $.001 par value: Authorized shares - 100,000,000; issued shares - 39,747,659 and 39,612,659, outstanding shares - 27,494,157 and 27,359,157 as of December 31, 2020 and 2019, respectively 39,748 39,613
Additional paid-in capital 98,013,079 96,105,851
Treasury stock, shares held at cost - 12,253,502 (18,929,915) (18,929,915)
Accumulated deficit (50,676,351) (41,351,078)
Total stockholders’ equity 28,446,561 35,864,471
Total liabilities and stockholders’ equity $ 30,072,432 $ 37,452,496